RxDoctor Payments Data

Earl Armstrong, MD

Pulmonary Disease · Washington, DCNPI 1205944428

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 76 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by GSK at 45.1% of the total. Reporting peaked in 2019 at $715 and has fallen 66.4% since, to $240 in 2025.

$1,643in general payments, 2019–2025

Across 76 payments — averaging $21.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$742
  • Mallinckrodt Hospital Products Inc.$370
  • AstraZeneca$154
  • Mallinckrodt Enterprises LLC$144
  • United Therapeutics Corporation$48
  • ANI Pharmaceuticals, Inc.$29
  • plus $156 from 8 others

What the payments were for

  • Food & beverage$1,643100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,643 in reported general payments places this provider in the 65th percentile of 56 pulmonary disease providers in District of Columbia.

See all pulmonary disease providers in District of Columbia

Medicare billing

Part B allowed, 2024
$36,699
Medicare patients
114
Services billed
359

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Spiriva RespimatTiotropium Bromide51$27,328
JardianceEmpagliflozin14$10,003
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$9,962
Breo ElliptaFluticasone/Vilanterol14$5,709
Advair HfaFluticasone Propion/Salmeterol12$5,481
Albuterol Sulfate HfaAlbuterol Sulfate165$3,864
SymbicortBudesonide/Formoterol Fumarate16$3,842
Fluticasone-SalmeterolFluticasone Propion/Salmeterol28$3,824
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate16$2,976
Fluticasone Propionate HfaFluticasone Propionate15$2,411
Montelukast Sodium133$1,892
Fluticasone Propionate67$1,690
Wixela InhubFluticasone Propion/Salmeterol15$1,264
Atorvastatin Calcium19$256
Alendronate Sodium13$140

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimSpiriva Respimat, Jardiance$21$37,33165 claims
GSKTrelegy Ellipta, Breo Ellipta$742$15,67126 claims
AstraZenecaSymbicort$154$3,84216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 56 pulmonary disease providers in District of Columbia.

Other pulmonary disease in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →